CD274 and non-small cell lung carcinoma: Immune-checkpoint inhibitor treatment, either as monotherapy or combination therapy depending on PD-L1 expression, has been established as the standard of care for patients with locally advanced/metastatic NSCLC without actionable oncogenic driver [24].